Cannabis Leaf (PCFP) Apotheca Biosciences Provides Corporate Update Solving Opioid Addiction is Our First Priority


Seattle, WA , May 23, 2018 (GLOBE NEWSWIRE) -- Cannabis Leaf (OTC:PCFP) Apotheca Biosciences Provides Corporate Update – Solving Opioid Addiction is Our First Priority.

Apotheca Biosciences is a pioneering biotech company that focuses on the research and development of high-grade nutraceuticals and cosmetics. Apotheca Biosciences is a one-of-kind company that is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our research.

Our mission is to deliver meaningful benefits through technology to the world’s aging population. “The health of our customers takes precedence and our solid business strategy ensures our focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our research,” said Sam Talari, Acting CEO of Apotheca Biosciences.

Apotheca Bioscience’s products include transdermal, sublingual and nasal delivery technologies for accurate and controlled dosing of cannabinoids. The transdermal technology includes CannaDerm, Canna-AcnePlus, Canna-Derme AD and Canna-EyeSol. Sublingual rapid delivery technology has been developed, and the products include CannaRapid, Canna-Oragel, and Canna Orsol. NasaCann, which is a nasal delivery technology, has been developed for the direct brain delivery for inhalable cannabinoid nanoparticles. With a partner company, Apotheca has also developed a CBD Hemp bar and CBD Oil.

Our cutting-edge R&D strategy is our blueprint and key driver for all our efforts. We harness interdisciplinary technology scouting and out-of-the box thinking to innovate and bring the best technology solutions for our customers. With a committed and motivated team of leaders, our excellent team of scientists together with the feedback from the Scientific Advisory Board, we set high standards in our R & D.

Application Areas - Opioid Addiction in US - CannaRAPID™ might be the answer for treating opioid addiction

United States is in the middle of an unprecedented opioid epidemic; Since 1999, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prescription pain medication deaths remain far too high, and in 2014, the most recent year on record, there was a sharp increase in heroin-involved deaths and an increase in deaths involving synthetic opioids such as fentanyl. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.

Early data coming out of states where marijuana laws have been passed suggest that even as conventionally used, marijuana may be playing a role in offsetting the opioid addiction epidemic. Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.

Our studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. There is at least partial evidence that cannabinoid compounds can relieve from depression. Apotheca Biosciences is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of CannaRAPID for opioid addiction.

Apotheca Biosciences has built several strategic relations with physician groups and other healthcare entities to enhance the vision and mission of the company. The company also has joint development research with NuvusGro, a cannabis grow company and CB Scientific, an innovative medical device company. Our experienced and seasoned team of leaders push the boundaries of nature and science. Our team includes John Verghese, Deirdre Fernandes, Sam Talari and Dr. Steve Bucami. We are working diligently to bring on board world renown scientist to help us facilitate our growth. 

If you would like more information on Apotheca’s products, please visit: www.apothecabiosciences.com/products-pipeline.

About Apotheca Biosciences Inc.

Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.

To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

                    

        

Contact Data